And as a PI on that study, he says, look, we have a new pharmaceutical agent that’s going to help with treatment a. And of course, that will be used in combination with treatment B. So the PI on the study is saying that he thinks the combination treatment of a weight loss medication similar to prior work and bariatric surgery that had much higher weight loss numbers or diet and exercise that had all the variance that we’ve seen over decades of different methodologies there. But this one does seem to be a good agent for treatment a. And then will need to be combined with treatment b to fully treat the sleep suffocation that the patients will have. So don’t trust me, the CEO of the company that makes the therapeutic, trust the primary investigator that’s saying, combination treatment has worked for decades and will work for decades.
I would expect that to be the outcome the trial. And in terms of working with Big Pharma on this, I think they’re very focused on other areas like obesity and diabetes, but as much as we can get their attention to talk about sleep and sleep health and to do their D2P advertising to talk about the importance of sleep and sleep health. I think combined with the Apples and the Samsungs and the Googles of the world talking about it, it will be a huge positive for of us in the sleep apnea treatment industry. Thanks for the question, Anthony.
Operator: Thank you. Next question is coming from Mike Matson from Needham & Company. Your line is now live.
Michael Matson: Yes. Thanks for taking my question. I guess I’ll just ask one on Philips. So I think they’ve talked about relaunching their flow generators in some of the OUS markets, just curious what you’re seeing there? Have you seen that happening? And have they been able to recapture share anywhere?
Michael Farrell: Yes. Thanks for the question, Mike. And yes, certainly in tens of countries in Europe and Asia. We are in full competition with all the global players, including the company you mentioned and the large regionals from Europe and from Asia and have been for many quarters. So they’ve come back in masks and devices across tens of countries in Europe and Asia. And their goal there when they come back, if they’ve been out for a year or two, depending on the time they’re out of each market is to fight their way from the bottom. They’ve got zero percent new patient start share when they first come back in and they’re trying to fight their way up. And in general, they had to fight against the number two, the number three and the number four player who don’t have like ResMed has the leading technology, the best AirSense platform, right.
The AirSense 11 globally is the best platform in all 140 countries. The second best platform in, I would say, all 140 countries is the AirSense 10 platform. So their goal is to then fight against regional player from Europe with the number three or a regional player from Asia, with the number four in the country that they’re coming back. And so we’re seeing that country by country. We’re seeing them fight for that share at the low end. It’s our focus as the market leader is on growing the market. And I think they’re a fair competitor. We’ve competed against them for decades since they bought Respironics. And in general, we’ve won and taken share. We were winning and taking share from them in 2019. We’re winning and taking share from the 2023 and 2024 as they come back country by country.
And if and when they come back to the U.S. marketing devices, by the way, they’re already here on masks, never left, and we’ve been competing and leading them there. I look forward to them coming back to the U.S. market so we can get any stock overhang away about what’s it going to look like and what it’s going to look like is what it looks like in all the other tens of countries where they fight for share from the bottom and work their way up. And I look forward to competition, a healthy competition. And we seem to do very well in it because we’ve got the smallest, quietest, most comfortable, most connected and most intelligent solutions, and it’s really about that. It’s about the value you provide getting that patient to the right care, lowering the cost and improving adherence.
And we’ve done a great job, and I like all global competition in the space.
Operator: Thank you. Your next question is coming from Suraj Kalia from Oppenheimer. Your line is now live.
Suraj Kalia: Hey, Mick, can you hear me all right?
Michael Farrell: Got you loud and clear, Suraj.
Suraj Kalia: Congrats on the nice quarter. So Mick, in the 2030 operating model, right? If I got your commentary right, ResMed brand and profitability, velocity of product control some of these things that you highlighted, I guess, way does Compliance Coach fit within the 2030 strategic model? More specifically, I’m just trying to understand how do you measure the ROI in the Compliance Coach. And I presume this is going to be a primarily a reactive AI model. Any additional clarity would be great? Thanks.
Michael Farrell: Well, thanks, Suraj. I could spend the rest of the time answering that call around the 2030 operating model. I’ll just briefly talk about it and then talk specifically about Compliance Coach. Our 2030 operating model, yes, it’s the three tenets, right? The three tenets product-led, customer-centric brand enhanced. ResMed has always been product led, but now we have a Global Chief Product Officer, whose sole role is to curate that product portfolio with an amazing team of hundreds of engineers and marketers to bring the great innovation to market. So we’ll measure the success on that on product velocity, how quickly do we bring innovation to market, time to market, time to success. Customer-centric. We’ve always been customer-centric.
